Biotechnology Assets Sa Stock Net Asset
| BST Stock | 0.31 0.01 3.13% |
Biotechnology Assets SA fundamentals help investors to digest information that contributes to Biotechnology Assets' financial success or failures. It also enables traders to predict the movement of Biotechnology Stock. The fundamental analysis module provides a way to measure Biotechnology Assets' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biotechnology Assets stock.
Biotechnology |
Biotechnology Assets SA Company Net Asset Analysis
Biotechnology Assets' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Biotechnology Assets SA has a Net Asset of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all Spain stocks average (which is currently at 0.0).
Biotechnology Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotechnology Assets' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotechnology Assets could also be used in its relative valuation, which is a method of valuing Biotechnology Assets by comparing valuation metrics of similar companies.Biotechnology Assets is currently under evaluation in net asset category among its peers.
Biotechnology Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.0647 | |||
| Profit Margin | (0.92) % | |||
| Operating Margin | (0.63) % | |||
| Shares Outstanding | 48.35 M | |||
| Shares Owned By Insiders | 51.21 % | |||
| Revenue | 3.28 M | |||
| Gross Profit | 3.01 M | |||
| EBITDA | (1.04 M) | |||
| Book Value Per Share | 0.1 X | |||
| Number Of Employees | 33 | |||
| Beta | 1.51 | |||
| Market Capitalization | 13.64 M | |||
| Annual Yield | 0.53 % |
About Biotechnology Assets Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotechnology Assets SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Assets using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Assets SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Biotechnology Stock
Biotechnology Assets financial ratios help investors to determine whether Biotechnology Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Assets security.